New approach for delivery of DNA-encoded monoclonal antibodies (DMAbs) has been reported by Wistar scientists. This new technology allows direct production of monoclonal antibody-like molecules in living animals.
Researchers at The Wistar Institute have created a drug candidate for cancers associated with Epstein-Barr Virus (EBV), the virus that causes infectious mononucleosis.
Researchers at The Wistar Institute have described a novel role of nicotinamide adenine dinucleotide (NAD+) metabolism in the ability of senescent cells to release tumor-promoting molecules.
Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma more sensitive to the attack of killer T cells.
The Wistar Institute announces that it was awarded more than $16M in federal research funds in support of its groundbreaking research in cancer, immunology and infectious diseases.
A novel, synthetic DNA vaccine developed at The Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South America, that has the potential to become a global emerging viral threat.
Wistar scientists and collaborators demonstrated the utility of an optimized synthetic DNA vaccine platform for rapidly inducing immunity against unique combinations of tumor neoantigens.
Wistar, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc. announce the FDA has approved the initiation of a first-in-human clinical trial investigating safety and tolerability of a novel synthetic DNA-encoded monoclonal antibody (DMAb) therapeutic technology for the prevention of Zika virus infection.
Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cholesterol levels in the bloodstream.
Wistar researchers have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and facilitate tumor cell seeding and establishment of metastasis.
A novel synthetic DNA vaccine developed based on technology pioneered by Wistar scientists offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research.
Wistar scientists have unraveled a mechanism of resistance to EZH2 inhibitors in ovarian cancers with mutations in the ARID1A gene.
Wistar scientists and collaborators demonstrate for the first time that through engineering constructs, they can express DNA-encoded monoclonal antibodies (DMAbs) targeting CTLA-4, an important cancer checkpoint molecule that blocks anti-cancer immunity.
Wistar scientists have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer.
A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies for the treatment of chronic viral-associated cancers and viral infections utilizing the first genetically encoded checkpoint inhibitor that can be given via vaccination.
Wistar scientists have engineered a synthetic DNA vaccine shown to produce broad immune responses against these H3N2 viruses.
A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically greater antitumor activity than either inhibitor alone, according to research from The Wistar Institute that was published online in Cancer Research.
Wistar scientists have applied their synthetic DNA technology to engineer a novel eCD4-Ig anti-HIV agent and to enhance its potency in vivo, providing a new simple strategy for constructing complex therapeutics for infectious agents as well as for diverse implications in therapeutic delivery.
Wistar received more than $5.5 million in grants and awards from local foundations, and national and international funding agencies to support research, education and training at the Institute.
Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute.
Wistar and Harbour BioMed announce they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases.
Wistar and Ben Franklin Technology Partners of Southeastern Pennsylvania (Ben Franklin), a nonprofit conglomerate of partners providing direct/seed funding, mentorship and networks to strengthen enterprise development, have signed a Memorandum of Understanding (MoU) to accelerate the advancement of early-stage life sciences start-ups coming out of Wistar.
Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.
Wistar and partners at the Perelman School of Medicine, University of Pennsylvania; Inovio Pharmaceuticals; and GeneOne Life Science were recognized among the Top 10 Clinical Research Achievement Awards by the Clinical Research Forum for their groundbreaking phase 1 DNA-based Zika vaccine research – the first trial of a Zika vaccine in humans, which proved safe and effective.
An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not a preferential biomarker to identify HIV silent reservoirs within the immune system of patients undergoing antiretroviral therapy (ART), as proposed by a recent landmark study.
Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models.
Wistar researchers have identified a novel therapeutic vulnerability in NRAS mutant melanoma and an effective strategy to address it, using a combination of two clinically relevant inhibitors, according to study results published online in EMBO Molecular Medicine.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Wistar and YourEncore, Inc., a life sciences and consumer goods consulting company engaging highly experienced, top talent industry experts, have signed a Memorandum of Understanding (MoU) to help accelerate the advancement of Wistar's early-stage discoveries, start-ups and international collaborations.
A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma.
According to a new study by The Wistar Institute, EZH2 inhibitors that are currently in clinical development for hematological malignancies and solid tumors may be effectively targeted to epithelial ovarian cancers overexpressing the CARM1 protein.
A new study conducted by researchers at The Wistar Institute revealed how a key protein residing in the endoplasmic reticulum (ER) helps cells respond to stress. This process is especially important for B cells to respond to severe stress conditions and their ability to produce antibodies. The research was published online in the Journal of Cell Biology.
Wistar is pleased to announce it has been awarded a $1,494,972 grant by the Bill & Melinda Gates Foundation to advance a DNA-based vaccine candidate for protection against malarial infection utilizing a synthetic DNA platform created in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer Research.
Immortalized human skin cells that look like a psychedelic otherworldly galaxy and a living algae colony releasing its daughter colonies that could be mistaken for Pacman gobbling up ghosts are just two of the winning images from the 2017 Nikon Small World competition of photomicrography–photography taken through microscopes–that arrive at The Wistar Institute with an opening reception on Jan. 19.
Wistar researchers have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers without BRCA1 and BRCA2 gene mutations.
Wistar scientists revealed the mechanism implicated in the defective function of tumor-associated dendritic cells (DCs), a specialized type of immune cells that expose the antigens on their surface to activate the T cells
Wistar researchers discovered a novel form of crosstalk among tumor cells and other cell types in the tumor microenvironment, elucidating the mechanism of action of an immunotherapeutic strategy that inhibits tumor-associated macrophages (TAMs) and instructing a more effective use of this therapeutic approach. This work was published online in Cancer Cell.
Wistar scientists have secured more than $16.5 million in funding throughout the summer and early fall of 2017.
The collaboration will further advance a canine melanoma vaccine and other vaccines for cancer and infectious diseases in animals
Researchers at The Wistar Institute have uncovered new aspects of the three-dimensional organization of the genome, specifically how the genetic material is compacted and de-compacted in a timely fashion during the different phases of the cell cycle.
The Wistar Institute, an international leader in biomedical research in the fields of cancer, immunology and infectious diseases, announces Kavitha Sarma, Ph.D., assistant professor in Wistar’s Gene Expression and Regulation Program, has been awarded the National Institutes of Health (NIH) Director’s New Innovator Award (DP2) for her research on “Epigenetic regulation through the formation and resolution of R loops.”
A study conducted at The Wistar Institute has led to the identification of a slowly proliferating and highly invasive melanoma cell subpopulation, characterized by production of a protein associated with invasive behavior.
In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells (“TABs”) in melanoma progression and resistance to targeted therapy.
A novel mitochondrial variant of the protein Syntaphilin, or SNPH, which orchestrates the choice between cancer cell proliferation and metastasis in response to oxygen and nutrient shortage in the tumor microenvironment, has been identified by researchers at The Wistar Institute.
T lymphocytes found in tumors and implicated in killing tumor cells cope with the shortage of oxygen and nutrients in the tumor microenvironment by using fat as the main source of energy. Promoting a switch from glucose to fatty acid to generate energy enhances T cell antitumor activity.
Wistar scientists have described a correlation between a key melanoma signaling pathway and a novel class of drugs being tested in the clinic as adjuvant therapy for advanced melanoma, providing useful information for a more effective use of this type of treatment.
The Wistar Institute is pleased to announce that distinguished scientist Dario C. Altieri, M.D., Wistar president and CEO and director of the Institute’s Cancer Center, has been awarded an Outstanding Investigator Grant (R35) by the National Institutes of Health (NIH) for high-caliber research exploring “tumor plasticity.” This highly coveted NCI program grant totals nearly $8 million over seven years.
A study led by Wistar scientists describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific protein.
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology
Wistar recently appointed John Fry and Morton Collins, Ph.D., to its Board of Trustees.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right